Loading... Please wait...
Sort by:

therapy-trends-jpg.jpg
Therapy Trends
reports deliver critical and unbiased intelligence derived from in-depth interviews with the world’s foremost thought leaders on the current and future treatment landscapes in major disease areas. Research is focused on the major battlegrounds for market share and answers critical business questions about potential product positioning and competitiveness. Through continuous monitoring and frequent re-engagement with stakeholders, the FirstWord Therapy Trends analyst team delivers quarterly updates with each report ensuring insights remain current and relevant.

  • Diabetes Mellitus: Early Stage Outlook [2018]
    Learn More Diabetes Mellitus: Early Stage Outlook [2018]
    Are novel technologies set to revolutionise diabetes?  Diabetes is a chronic disease that requires lifelong management; however, rapid developments in innovative diabetes technologies (D-tech) have greatly improved...
  • Non-Small Cell Lung Cancer: KOL Insight [2018]
    Learn More Non-Small Cell Lung Cancer: KOL Insight [2018]
    What are the next key opportunities for growth of IOs in NSCLC? The growth of IO in NSCLC continues unabated. As Merck & Co.'s Keytruda becomes increasingly dominant in the first-line metastatic setting, will it be...
  • Chronic Lymphocytic Leukaemia: KOL Insight [2018]
    Learn More Chronic Lymphocytic Leukaemia: KOL Insight [2018]
    How will targeted therapy combinations transform the treatment of CLL? Chemoimmunotherapy regimens incorporating Rituxan/MabThera have traditionally been the cornerstone of CLL treatment. How is this expected to change?...
  • Atopic Dermatitis: KOL Insight [2018]
    Learn More Atopic Dermatitis: KOL Insight [2018]
    Will new pipeline therapies transform the treatment of atopic dermatitis? New pipeline agents look set to transform the treatment of moderate-to-severe atopic dermatitis. Dupixent (dupilumab; Regeneron/Sanofi) has...
  • Bladder Cancer: KOL Insight [2018]
    Learn More Bladder Cancer: KOL Insight [2018]
    How can immune checkpoint inhibitors differentiate themselves in the competitive Bladder cancer space? Five PD-1/PD-L1 immune checkpoint inhibitors are approved for bladder cancer, but how are these therapies faring on...
  • Psoriasis: KOL Insight [2018]
    Learn More Psoriasis: KOL Insight [2018]
    How will next-generation biologics change the psoriasis treatment landscape?  The treatment of psoriasis is evolving and the range of therapies is set to diversify with the approval and introduction of novel...
  • KOL Insight: Oncology Solid Tumour Review (2018 Q2)
    Learn More KOL Insight: Oncology Solid Tumour Review (2018 Q2)
    KOLs speak out on recent events in the solid tumour landscape With so much happening in the solid tumour treatment landscape it’s important to understand how things are likely to evolve. Based on the insights of...
  • Future Innovations in Oncology: Early Stage Outlook [2018]
    Learn More Future Innovations in Oncology: Early Stage Outlook [2018]
    How is the Oncology treatment landscape expected to evolve over the next 10 years? Oncology treatment has undergone a dramatic shift over the past 20 years with many drugs entering the space greatly improving survival...
  • Renal Cell Carcinoma: KOL Insight [2018]
    Learn More Renal Cell Carcinoma: KOL Insight [2018]
    RCC: A new era of IO-based combination therapy The recent FDA approval of BMS’ Opdivo/Yervoy has pioneered a new immuno-oncology (IO)-based combination approach to the first-line treatment of RCC. How do KOLs view...
  • Multiple Myeloma: KOL Insight [2018]
    Learn More Multiple Myeloma: KOL Insight [2018]
    How do the multitude of emerging combination regimens stack up in MM? The treatment of multiple myeloma (MM) is rapidly evolving and the range of combination therapies is set to diversify with triplet and quadruple...
  • Gastric Cancer: KOL Insight [2018]
    Learn More Gastric Cancer: KOL Insight [2018]
    All change in the gastric cancer treatment landscape? KOLs speak out… The treatment of gastric cancer is rapidly evolving and the range of therapies is set to diversify with the approval and introduction of novel...
  • Nonalcoholic Steatohepatitis (NASH): KOL Insight [2018]
    Learn More Nonalcoholic Steatohepatitis (NASH): KOL Insight [2018]
    Are novel therapies set to revolutionise NASH? No drug therapies have been approved for patients with nonalcoholic steatohepatitis (NASH) but this could all change in the next 3-5 years. Four late-stage pipeline...
  • Breast Cancer: KOL Insight [2018]
    Learn More Breast Cancer: KOL Insight [2018]
    How is biosimilar trastuzumab expected to fare in breast cancer? Biosimilar trastuzumab is now available in Europe, and key opinion leaders (KOLs) weigh in on how this product is expected to fare after years of...
  • CAR-T Therapy in Haematological Malignancy: Early Stage Outlook: KOL Insight [2018]
    Learn More CAR-T Therapy in Haematological Malignancy: Early Stage Outlook: KOL Insight [2018]
    How are CAR-T cell therapies revolutionising treatment of haematological cancer? Last year witnessed the FDA approval of the first two anti-CD19 CAR-T cell therapies in two types of blood cancer. Find out how these...
  • Chronic Obstructive Pulmonary Disorder (COPD): KOL Insight [2018]
    Learn More Chronic Obstructive Pulmonary Disorder (COPD): KOL Insight [2018]
      Established brands, generics, biologics and new MOAs fight for supremacy in the COPD treatment landscape Established treatments are coming under pressure from generics, new combinations, biologics and new MOAs...
  • Ovarian Cancer : KOL Insight [2018]
    Learn More Ovarian Cancer : KOL Insight [2018]
    How will new combination regimens impact the ovarian cancer treatment landscape? PARP inhibitors are firmly entrenched in the treatment algorithm for ovarian cancer, and their role continues to diversify. How will...

customer.service@firstwordpharma.com

All Contents Copyright © 2018 Doctor's Guide Publishing Limited All Rights Reserved